<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02102672</url>
  </required_header>
  <id_info>
    <org_study_id>13-229</org_study_id>
    <nct_id>NCT02102672</nct_id>
  </id_info>
  <brief_title>Trimetazidine in Pulmonary Artery Hypertension</brief_title>
  <official_title>Comprehensive Evaluation of Right Ventricular Function, Ventricular Remodeling and Micro RNA Profiling in Pulmonary Artery Hypertension: Effects of a Fatty Acid Oxidation Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo Nacional de Desarrollo Científico y Tecnológico, Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary artery hypertension (PAH) is a chronic and progressive disease that affects 15
      persons per million. Although current therapy has improve disease prognosis, PAH still has a
      poor survival, with a median survival of 2.8 years after diagnosis. In the last few years new
      key elements in PAH pathogenesis have been discovered, such as the role of metabolism in
      disease onset and progression. In fact, PAH pulmonary smooth muscle cells switch into a
      glycolytic phenotype which resembles the metabolism of cancer cells. The investigators
      hypothesis is that &quot;fatty acid oxidation inhibition reverts the PAH adverse phenotype by
      restoring mitochondrial function and morphology, decreasing proliferation and restoring
      apoptosis susceptibility in pulmonary smooth muscle cells &quot;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in right ventricular (RV) function</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in RV function assessed by echo 3d (strain-strain rate)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in exercise capacity</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in exercise capacity assessed by 6 minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in Borg dyspnea index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biomarkers</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in B-type natriuretic peptide, galectin-3 and rho-kinase activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening</measure>
    <time_frame>3 months</time_frame>
    <description>Time to first PAH related medical event (ER evaluation, hospitalization or death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pulmonary Artery Hypertension</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 pill bid, 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trimetazidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimetazidine 35 mg bid for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine</intervention_name>
    <arm_group_label>Trimetazidine</arm_group_label>
    <other_name>Vastarel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PAH patients belonging to the following subgroups of the updated Dana Point
             Classification Group 1

               1. Idiopathic PAH

               2. Heritable PAH

               3. Drug or toxin-induced PAH

               4. PAH associated with connective tissue disease

               5. PAH associated to congenital heart disease with simple systemic-to-pulmonary
                  shunt at least 1 year after surgical repair

               6. PAH associated to HIV infection

          -  Documented hemodynamic diagnosis of PAH by right ventricular catheterization performed
             any time prior to screening

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients belonging to the subgroups of the updated Dana Point Classification Group I
             not listed in the inclusion criteria

          -  Patients belonging to the groups 2-5 of the updated Dana Point Classification Group

          -  Moderate to severe chronic pulmonary obstructive disease

          -  Documented left ventricular dysfunction

          -  Severe renal impairment (Serum creatinine &gt; 2.5 mg/dL)

          -  Patients who are receiving or have been receiving any investigational drugs within 1
             month before the baseline visit

          -  Acute or chronic impairment (other than dyspnea) limiting the ability to comply with
             study requirements

          -  Psychotic, addictive or other disorder limiting the ability to provide informed
             consent or to comply with study requirements

          -  Life expectancy less than 12 months

          -  Females who are lactating or pregnant or those who plan to become pregnant during the
             study

          -  Known hypersensitivity to any of the excipients of the drug formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo F Castro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo F Castro, MD</last_name>
    <phone>+56223543334</phone>
    <email>pcastro@med.puc.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hugo E Verdejo, MD, PhD</last_name>
    <phone>+569223543624</phone>
    <email>hverdejo@med.puc.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinico Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvana A Llevaneras, RN</last_name>
      <phone>+56223548236</phone>
      <email>sllevane@med.puc.cl</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

